The Bigger Picture: What Patent Expiry Means for Metabolic Medicine The semaglutide patent expiry biosimilar wave represents a structural inflection point for metabolic medicine globally, even if US patients face a delayed version of that inflection
Now, that landscape has changed
ShedRx Widest Formulary, Including FDA-Approved Pills and Brand-Name GLP-1 ShedRx is the only program in this comparison that offers brand-name Wegovy, brand-name Zepbound, and the FDA-approved oral GLP-1 pill Foundayo , in addition to compounded semaglutide and tirzepatide
Tirzepatide targets GLP-1 and GIP receptors, while semaglutide targets only GLP-1 receptors
The performance-enhancing argument In weight-sensitive endurance sports, reducing body mass while maintaining power output directly improves performance
Semaglutide is administered subcutaneously, meaning into the fat layer beneath the skin